Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir prophylaxis for hepatitis B reactivation in occult HBV infection during finite-duration immunosuppression for rheumatologic disease
2015-000570-35Phase 3Terminated
- Sponsor
- University of Naples Federico II
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tenofovir disoproxil fumarate in Occult Hepatitis B Infection (OBI), sponsored by University of Naples Federico II. Primary endpoint: HBV virologic non-reactivation at end of study. Started Jan 2021; status: terminated.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Occult Hepatitis B Infection (OBI)
Beyond the preview
Go deeper on 2015-000570-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000570-35.